Gutkowski A, Bedard P, Del Carpio J, Hebert J, Prevost M, Schulz J, Turenne Y, Yeadon C
Division of Immunology and Rheumatology, St. Mary's Hospital, Montreal, Quebec, Canada.
J Allergy Clin Immunol. 1988 May;81(5 Pt 1):902-7. doi: 10.1016/0091-6749(88)90948-7.
The efficacy and safety of loratadine, 40 mg once daily, were compared with terfenadine, 60 mg twice daily, and placebo in controlling symptoms of ragweed hay fever. The study was a randomized, multicentric, parallel-group, double-blind design involving 280 patients divided into three groups receiving either loratadine, terfenadine, or placebo for a period of 14 days in the autumn of 1984. Both loratadine and terfenadine demonstrated a statistically greater reduction in symptom score compared to placebo. They were not statistically different from each other, and there was no statistical difference in the incidence of side effects between the two drugs.
将氯雷他定(每日一次,40毫克)与特非那定(每日两次,60毫克)及安慰剂在控制豚草花粉热症状方面的疗效和安全性进行了比较。该研究采用随机、多中心、平行组、双盲设计,涉及280名患者,这些患者被分为三组,在1984年秋季接受为期14天的氯雷他定、特非那定或安慰剂治疗。与安慰剂相比,氯雷他定和特非那定在症状评分上均有统计学意义上的显著降低。二者在统计学上无差异,且两种药物的副作用发生率也无统计学差异。